HCW Biologics Inc.

HCW Biologics Inc. (HCWB) priced its initial public offering on Jul 21, 2021 at $8.00 per share, within its $8.00–$10.00 range, raising $56M, and listed on Nasdaq Global Market. At the IPO price its market capitalization was about $285.2M. Benchmark was lead-left underwriter, joined by Revere. Orrick advised the company and Sheppard Mullin advised the underwriters.

HCW Biologics Inc. is a preclinical-stage biopharmaceutical company developing immunotherapies aimed at age-related chronic low-grade inflammation, which it calls inflammaging. Its approach targets the link between this inflammation and diseases such as cancer, cardiovascular disease, diabetes and neurodegenerative and autoimmune disease.

Status

IPO

Ticker

HCWB

Exchange

Nasdaq Global Market

Priced

Jul 21, 2021

IPO price

$8.00

Price range

$8.00–$10.00

Raised

$56M

Market cap at IPO price

$285.2M

First filed

May 26, 2021

Underwriters

Benchmark and Revere

Company counsel

Orrick

Underwriters' counsel

Sheppard Mullin

Sector

Biotech & pharma

Country / state

FL

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.